Amitriptyline at low-dose and titrated for irritable bowel syndrome as second-line treatment in primary care (ATLANTIS): a randomised, double-blind, placebo-controlled, phase 3 trial.

Lancet 2023; 402: 1773-1785.

This study included 463 participants, and the outcome was analysed using an IBS symptom scoring system. After six months, patients who received Amitriptyline had significantly lower IBS scores (P=0.0079). Around one fifth of patients in both groups discontinued their medication.

Comment: Useful study with another option for management of this common disease.